| Biomarker ID | 1560 |
| PMID | 9563891 |
| Year | 1998 |
| Biomarker | Versican |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | RR: 7.66 (95% CI: 2.53-23.18) |
| Effect on Pathways | Pathway include: Chondroitin sulfate/dermatan sulfate metabolism; Integrin Pathway; ERK Signaling; Glycosaminoglycan metabolism; Phospholipase-C Pathway |
| Experiment | Progression Vs No Progression |
| Type of Biomarker | Prognostic |
| Cohort | 11 men with no history of prostate cancer were selected along with 43 men with prostate cancer |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0003 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |